Cleveland BioLabs (CBLI) Given News Sentiment Rating of 0.23

News articles about Cleveland BioLabs (NASDAQ:CBLI) have trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.265478728781 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Cleveland BioLabs (CBLI) opened at 3.49 on Friday. The stock’s market cap is $39.36 million. Cleveland BioLabs has a 52 week low of $1.22 and a 52 week high of $5.55. The stock’s 50 day moving average is $3.04 and its 200 day moving average is $2.97.

Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.50) earnings per share for the quarter. The company had revenue of $0.21 million for the quarter. Cleveland BioLabs had a negative net margin of 253.09% and a negative return on equity of 61.18%. On average, equities analysts forecast that Cleveland BioLabs will post ($0.16) EPS for the current year.

Separately, ValuEngine lowered shares of Cleveland BioLabs from a “hold” rating to a “sell” rating in a research note on Thursday, June 29th.

TRADEMARK VIOLATION NOTICE: “Cleveland BioLabs (CBLI) Given News Sentiment Rating of 0.23” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Insider Buying and Selling by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with's FREE daily email newsletter.

Leave a Reply